ADARx Pharmaceuticals, Inc. ADRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.13M | 5.59M | 3.45M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.13M | 5.59M | 3.45M | -- | -- |
| Cost of Revenue | 89.87M | 82.20M | 71.51M | -- | -- |
| Gross Profit | -83.74M | -76.61M | -68.06M | -- | -- |
| SG&A Expenses | 22.56M | 20.92M | 20.30M | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 112.43M | 103.12M | 91.81M | -- | -- |
| Operating Income | -106.30M | -97.53M | -88.37M | -- | -- |
| Income Before Tax | -87.87M | -80.20M | -73.09M | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -87.87 | -80.20 | -73.09 | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -87.87M | -80.20M | -73.09M | -- | -- |
| EBIT | -106.30M | -97.53M | -88.37M | -- | -- |
| EBITDA | -105.12M | -96.43M | -87.36M | -- | -- |
| EPS Basic | -7.74 | -7.06 | -6.43 | -- | -- |
| Normalized Basic EPS | -4.84 | -4.41 | -4.02 | -- | -- |
| EPS Diluted | -7.74 | -7.06 | -6.43 | -- | -- |
| Normalized Diluted EPS | -4.84 | -4.41 | -4.02 | -- | -- |
| Average Basic Shares Outstanding | 45.41M | 45.44M | 45.45M | -- | -- |
| Average Diluted Shares Outstanding | 45.41M | 45.44M | 45.45M | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |